Cinaciguat
![]() | |
Systematic (IUPAC) name | |
---|---|
4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl) phenyl]methoxy}phenyl)ethyl]amino}methyl) benzoic acid | |
Clinical data | |
intravenous (?) | |
Identifiers | |
329773-35-5 ![]() | |
None | |
PubChem | CID 9808022 |
ChemSpider |
7983781 ![]() |
UNII |
59K0Y58UAD ![]() |
Chemical data | |
Formula | C36H39NO5 |
565.697 g/mol | |
SMILES
| |
| |
![]() |
Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.
Mechanism of action
Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation.[1]
See also
- Riociguat, another drug stimulating sGC, but with a different mechanism
- PDE5 inhibitors act further downstream in the nitric oxide signalling pathway, reducing cyclic GMP degradation.
References
- ↑ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009